FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081991489> ?p ?o ?g. }

• W2081991489 endingPage "986" @default.
• W2081991489 startingPage "980" @default.
• W2081991489 abstract "BACKGROUND The clinical effects of targeting HER-2 in prostate carcinoma are not known. This study explored the feasibility of molecular profiling to determine the correlation between HER-2 expression, hormonal sensitivity, and the antitumor effects of trastuzumab and paclitaxel in patients with prostate carcinoma. METHODS Patients with progressive androgen dependent (AD) and androgen independent (AI) prostate carcinoma were eligible to participate in the study. HER-2 expression was assessed on pretreatment tissue specimens, and patients were then assigned to one of four treatment groups: AD HER-2 positive, AD HER-2 negative, AI HER-2 positive, and AI HER-2 negative. They were treated with weekly trastuzumab at a dose of 2 mg/kg (after a 4 mg/kg loading dose) until they experienced disease progression, when weekly paclitaxel at 100 mg/m2 was added. RESULTS The authors screened 130 patients for HER-2 expression. In total, 23 patients were treated. Six eligible patients had HER-2 positive disease; therefore, only the AI HER-2 negative arm accrued to completion. All patients (100%) experienced disease progression on trastuzumab alone at or before the first 12 weeks of treatment. Fifteen patients received combined therapy: Seven patients (47%) experienced disease progression, 5 patients (33%) had stable disease, and 3 patients (20%) had a decline ≥ 50% in prostate specific antigen PSA level or in soft tissue disease. HER-2 overexpression was found in significant proportions only in AI metastatic tissue samples (42% HER-2 positive; 95% confidence interval, 14–60%). In three of nine matched pairs, the AD prostate biopsy was HER-2 negative, and the AI metastatic sample was HER-2 positive. CONCLUSIONS Trastuzumab is not effective as a single agent for the treatment of patients with AI HER-2 negative tumors. HER-2 expression varies by clinical state in patients with prostate carcinoma: Accurate HER-2 profiling requires sampling metastatic tissue in patients with metastatic disease. Further development of trastuzumab for the treatment of patients with metastatic prostate carcinoma is not feasible until more reliable and practical methods of sampling metastatic disease are developed to identify patients with HER-2 positive tumors. Cancer 2002;94:980–6. © 2002 American Cancer Society. DOI 10.1002/cncr.10339" @default.
• W2081991489 created "2016-06-24" @default.
• W2081991489 creator A5010536553 @default.
• W2081991489 creator A5011925629 @default.
• W2081991489 creator A5017288060 @default.
• W2081991489 creator A5039147214 @default.
• W2081991489 creator A5054020569 @default.
• W2081991489 creator A5063435994 @default.
• W2081991489 creator A5072850546 @default.
• W2081991489 creator A5080635562 @default.
• W2081991489 date "2002-02-15" @default.
• W2081991489 modified "2023-10-09" @default.
• W2081991489 title "HER-2 profiling and targeting in prostate carcinoma" @default.
• W2081991489 cites W1580523172 @default.
• W2081991489 cites W1816774827 @default.
• W2081991489 cites W1966823692 @default.
• W2081991489 cites W1967819851 @default.
• W2081991489 cites W1982093899 @default.
• W2081991489 cites W2001627828 @default.
• W2081991489 cites W2014538286 @default.
• W2081991489 cites W2069237867 @default.
• W2081991489 cites W2072140252 @default.
• W2081991489 cites W2079816467 @default.
• W2081991489 cites W2089487481 @default.
• W2081991489 cites W2094455666 @default.
• W2081991489 cites W2095900336 @default.
• W2081991489 cites W2105829250 @default.
• W2081991489 cites W2118370975 @default.
• W2081991489 cites W2151453176 @default.
• W2081991489 cites W2159459001 @default.
• W2081991489 cites W2171724045 @default.
• W2081991489 cites W2318605753 @default.
• W2081991489 cites W2438565249 @default.
• W2081991489 cites W3106889297 @default.
• W2081991489 cites W53330856 @default.
• W2081991489 doi "https://doi.org/10.1002/cncr.10339" @default.
• W2081991489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11920466" @default.
• W2081991489 hasPublicationYear "2002" @default.
• W2081991489 type Work @default.
• W2081991489 sameAs 2081991489 @default.
• W2081991489 citedByCount "124" @default.
• W2081991489 countsByYear W20819914892012 @default.
• W2081991489 countsByYear W20819914892013 @default.
• W2081991489 countsByYear W20819914892014 @default.
• W2081991489 countsByYear W20819914892015 @default.
• W2081991489 countsByYear W20819914892016 @default.
• W2081991489 countsByYear W20819914892017 @default.
• W2081991489 countsByYear W20819914892019 @default.
• W2081991489 countsByYear W20819914892020 @default.
• W2081991489 countsByYear W20819914892021 @default.
• W2081991489 countsByYear W20819914892022 @default.
• W2081991489 countsByYear W20819914892023 @default.
• W2081991489 crossrefType "journal-article" @default.
• W2081991489 hasAuthorship W2081991489A5010536553 @default.
• W2081991489 hasAuthorship W2081991489A5011925629 @default.
• W2081991489 hasAuthorship W2081991489A5017288060 @default.
• W2081991489 hasAuthorship W2081991489A5039147214 @default.
• W2081991489 hasAuthorship W2081991489A5054020569 @default.
• W2081991489 hasAuthorship W2081991489A5063435994 @default.
• W2081991489 hasAuthorship W2081991489A5072850546 @default.
• W2081991489 hasAuthorship W2081991489A5080635562 @default.
• W2081991489 hasConcept C121608353 @default.
• W2081991489 hasConcept C126322002 @default.
• W2081991489 hasConcept C143998085 @default.
• W2081991489 hasConcept C2776235491 @default.
• W2081991489 hasConcept C2776694085 @default.
• W2081991489 hasConcept C2777292972 @default.
• W2081991489 hasConcept C2777546739 @default.
• W2081991489 hasConcept C2779786085 @default.
• W2081991489 hasConcept C2780192828 @default.
• W2081991489 hasConcept C2781406297 @default.
• W2081991489 hasConcept C2993388676 @default.
• W2081991489 hasConcept C44249647 @default.
• W2081991489 hasConcept C530470458 @default.
• W2081991489 hasConcept C71924100 @default.
• W2081991489 hasConcept C90924648 @default.
• W2081991489 hasConceptScore W2081991489C121608353 @default.
• W2081991489 hasConceptScore W2081991489C126322002 @default.
• W2081991489 hasConceptScore W2081991489C143998085 @default.
• W2081991489 hasConceptScore W2081991489C2776235491 @default.
• W2081991489 hasConceptScore W2081991489C2776694085 @default.
• W2081991489 hasConceptScore W2081991489C2777292972 @default.
• W2081991489 hasConceptScore W2081991489C2777546739 @default.
• W2081991489 hasConceptScore W2081991489C2779786085 @default.
• W2081991489 hasConceptScore W2081991489C2780192828 @default.
• W2081991489 hasConceptScore W2081991489C2781406297 @default.
• W2081991489 hasConceptScore W2081991489C2993388676 @default.
• W2081991489 hasConceptScore W2081991489C44249647 @default.
• W2081991489 hasConceptScore W2081991489C530470458 @default.
• W2081991489 hasConceptScore W2081991489C71924100 @default.
• W2081991489 hasConceptScore W2081991489C90924648 @default.
• W2081991489 hasIssue "4" @default.
• W2081991489 hasLocation W20819914891 @default.
• W2081991489 hasLocation W20819914892 @default.
• W2081991489 hasOpenAccess W2081991489 @default.
• W2081991489 hasPrimaryLocation W20819914891 @default.
• W2081991489 hasRelatedWork W2004918795 @default.
• W2081991489 hasRelatedWork W2031954916 @default.

• next